AIDS

1. BUZON L, Bernardino JI, Galindo Puerto MJ, Martin-Torres J, et al
   Genotyping not required for sustained effectiveness of long-acting cabotegravir plus rilpivirine: evidence from the RELATIVITY cohort.
   AIDS. 2025 Oct 23. doi: 10.1097/QAD.0000000000004388.
   

   >> Share

   
   

   
   BMJ

2. SARKAR S
   HIV: Five children in India are infected from contaminated blood donations.
   BMJ. 2025;391:r2310.
   

   >> Share

   
   

   
   Cancer

3. DUFF AJ, Junkins A, Chen L, Mannion K, et al
   The association between human papillomavirus type 16 seropositivity and oropharyngeal cancer among men living with HIV.
   Cancer. 2025;131:e70167.
   

   >> Share

   
   

   
   Cell

4. WILLIAMS WB, Alam SM, Ofek G, Erdmann N, et al
   Vaccine induction of heterologous HIV-1-neutralizing antibody B cell lineages in humans.
   Cell. 2025 Nov 1:S0092-8674(25)01195-X. doi: 10.1016/j.cell.2025.
   

   >> Share

   
   

   
   Clin Infect Dis

5. ROLLE C, Achhra A, Harbison C, Finkel D, et al
   Combined use of ibalizumab and lenacapavir for the treatment of multidrug-resistant HIV-1: A case series.
   Clin Infect Dis. 2025 Nov 3:ciaf597. doi: 10.1093.
   

   >> Share

   
   
6. SHORT WR, Ogbuagu OE
   New strategies for a vexing problem: injectables to the rescue for people with Multidrug-Resistant HIV.
   Clin Infect Dis. 2025 Nov 3:ciaf600. doi: 10.1093.
   

   >> Share

   
   

   
   HIV Med

7. BONI S, Debaudrap P, Kabore FN, Kasile-Pooda E, et al
   Long-term risk and predictors of high-risk human papillomavirus persistence after thermal ablation amongst women living with HIV in West Africa.
   HIV Med. 2025 Nov 3. doi: 10.1111/hiv.70138.
   

   >> Share

   
   
8. MISPELBAUM R, Hattenhauer T, Hoffmann C, Lehmann C, et al
   Effective and safe use of immune checkpoint inhibitors for non-small cell lung cancer in people living with HIV.
   HIV Med. 2025 Nov 5. doi: 10.1111/hiv.70136.
   

   >> Share

   
   
9. CHRISTENSEN AJ, Omann LR, Carlsson J, Baluku JB, et al
   Prevalence of current substance and hazardous alcohol use among people with HIV and tuberculosis disease and its impact on tuberculosis treatment outcomes: A systematic review.
   HIV Med. 2025 Nov 5. doi: 10.1111/hiv.70139.
   

   >> Share

   
   
10. ANDOH J, Taghavi K, Moono M, Basu P, et al
    Cervical intraepithelial neoplasia progression and regression among women living with HIV in Zambia.
    HIV Med. 2025 Nov 5. doi: 10.1111/hiv.70134.
    

    >> Share

    
    
11. BYRNE L
    BHIVA guidelines on the management of HIV in pregnancy and the postpartum period 2025.
    HIV Med. 2025;26:1757-1880.
    

    >> Share

    
    
12. DARLING KEA, Damas J, Frei AL, Frega S, et al
    Quality improvement report: Investigating barriers in HIV testing oncology patients to optimize HIV testing practice.
    HIV Med. 2025 Nov 2. doi: 10.1111/hiv.70140.
    

    >> Share

    
    
13. CALDERON M, Alarcon Y, Alave J, Lopez O, et al
    Bridging borders in HIV care education: Lessons from an online multidisciplinary international exchange programme.
    HIV Med. 2025;26:1887-1893.
    

    >> Share

    
    
14. COVA A, Ritchie CS, Godfrey M, Ghoshhajra B, et al
    Inflammatory profiles in older people with and without HIV in rural Uganda.
    HIV Med. 2025;26:1894-1901.
    

    >> Share

    
    

    
    Int J Cancer

15. NEWTON R, Tenet V, Mugisha J, Kimono B, et al
    Human papillomavirus infection and vaccination among young females in rural Uganda.
    Int J Cancer. 2025 Nov 6. doi: 10.1002/ijc.70227.
    

    >> Share

    
    

    
    J Acquir Immune Defic Syndr

16. UMUTONI V, Eavou R, Almirol E, Neumann MS, et al
    A Community Located Insurance Navigation Intervention to link Sexual and Gender Minorities in Status Neutral Care: Results from the NICE Randomized Controlled Trial.
    J Acquir Immune Defic Syndr. 2025 Nov 3. doi: 10.1097/QAI.0000000000003788.
    

    >> Share

    
    
17. WAMAKIMA B, Diouf K, Modest A, Macharia A, et al
    Pre-eclampsia Rates in Women with and without HIV in Modern ART Era in Botswana.
    J Acquir Immune Defic Syndr. 2025 Nov 6. doi: 10.1097/QAI.0000000000003791.
    

    >> Share

    
    
18. NGUYEN T, Chae JW, Ziemba L, Coletti A, et al
    Breast Milk Transfer and Infant Exposures to Dolutegravir, Tenofovir, and Tenofovir Alafenamide: Results from IMPAACT 2010/VESTED.
    J Acquir Immune Defic Syndr. 2025 Nov 6. doi: 10.1097/QAI.0000000000003796.
    

    >> Share

    
    
19. LAXMESHWAR C, Hegde A, Dange A, Mariyappan K, et al
    Virtual model for HIV self-testing demand generation and kit distribution: Results from the STAR III study in India.
    J Acquir Immune Defic Syndr. 2025 Nov 6. doi: 10.1097/QAI.0000000000003792.
    

    >> Share

    
    
20. DRUMRIGHT LN, Delaney JA, Crawford T, Whitney BM, et al
    Longitudinal associations between internalized HIV stigma and lower HIV antiretroviral therapy adherence among people with HIV.
    J Acquir Immune Defic Syndr. 2025 Nov 6. doi: 10.1097/QAI.0000000000003793.
    

    >> Share

    
    
21. HALLMARK CJ, France AM, Linley L, Lyss SB, et al
    Characteristics of HIV Time-Space Alerts in the United States, 2018-2021.
    J Acquir Immune Defic Syndr. 2025 Nov 6. doi: 10.1097/QAI.0000000000003795.
    

    >> Share

    
    

    
    J Virol

22. MATHUR T, Ahmed S, Parthasarathy D, Herschhorn A, et al
    Highly efficient production of HIV-1(AD8) gp120 in mammalian cells.
    J Virol. 2025 Nov 7:e0135925. doi: 10.1128/jvi.01359.
    

    >> Share

    
    

    
    Lancet

23. MEYER-RATH G, Jamieson L, Mudimu E, Snyman K, et al
    Who pays and what pays off in sexual and reproductive health? A review of the cost and cost-effectiveness of interventions and implications for future funding and markets.
    Lancet. 2025;406:2152-2167.
    

    >> Share

    
    
24. PETERS RPH, Grinsztejn B, Celum C, Mayer KH, et al
    Innovations in the biomedical prevention, diagnosis, and service delivery of HIV and other sexually transmitted infections.
    Lancet. 2025;406:2133-2151.
    

    >> Share

    
    
25. GRULICH AE, Mercer CH, Sturrock B, Baral S, et al
    Partial progress in sexual and reproductive health and rights: the influence of sociocultural, behavioural, structural, and technological changes on epidemiological trends.
    Lancet. 2025;406:2100-2118.
    

    >> Share

    
    
26. NGEMA N
    A rights-based imperative for young women.
    Lancet. 2025;406:2038-2040.
    

    >> Share

    
    
27. MAYER KH, Beyrer C, Cohen MS, El-Sadr WM, et al
    Challenges and opportunities in developing integrated sexual and reproductive health programmes.
    Lancet. 2025;406:2168-2190.
    

    >> Share

    
    

    
    Nat Med

28. KITYO C, Mambule IK, Musaazi J, Sokhela S, et al
    Cabotegravir and rilpivirine for treatment of HIV infection in Africa: week 96 results from the phase 3b randomized, open-label, noninferiority CARES trial.
    Nat Med. 2025 Nov 4. doi: 10.1038/s41591-025-04041.
    

    >> Share

    
    

    
    Nature

29. FIELDHOUSE R
    Antibody drugs show promise for treating bird flu and HIV.
    Nature. 2025 Nov 5. doi: 10.1038/d41586-025-03540.
    

    >> Share

    
    

    
    PLoS Comput Biol

30. DANKWA EA, Cavalli L, Balasubramanian R, Can MH, et al
    Calibration of transmission-dynamic infectious disease models: A scoping review and reporting framework.
    PLoS Comput Biol. 2025;21:e1013647.
    

    >> Share

    
    

    
    PLoS One

31. TAQIPANAHI A, Haromi ME, Shahri F, Landry A, et al
    Moral violations lead to demeaning: Non-disclosure of HIV undermines perceived psychological needs.
    PLoS One. 2025;20:e0335525.
    

    >> Share

    
    
32. FEKRI M, Bolhassani A, Movahedi M, Rahmati F, et al
    Simultaneous efficacy of IL-15 and the HSP70 fragments in increasing immunostimulatory effects of a HIV-1 DNA vaccine candidate against SCR HIV-1.
    PLoS One. 2025;20:e0336042.
    

    >> Share

    
    
33. LANGAT R, McRaven MD, Lorenzo-Redondo R, Muhomah T, et al
    Endocervix exhibits greater susceptibility to HIV-1 infection compared to ectocervix following ex vivo exposure to Transmitted/Founder HIV-1 variants.
    PLoS One. 2025;20:e0334510.
    

    >> Share

    
    
34. DAHIR HEROW A, Grace N, Kimera J, Nduwimana M, et al
    Prevalence and determinants of anemia among HIV-positive children in central Uganda: A cross sectional study.
    PLoS One. 2025;20:e0333825.
    

    >> Share

    
    
35. HASAN MS, Ni S, Kamal FB, Blossey MF, et al
    Sequestration and suppressed synthesis of oncogenic HMGA1 using engineered adenoviruses decreases human pancreatic and breast cancer cell characteristics.
    PLoS One. 2025;20:e0335934.
    

    >> Share

    
    

    
    Proc Natl Acad Sci U S A

36. HU L, Zhang A, Warshel A
    Exploring evolutionary trajectories of drug resistance.
    Proc Natl Acad Sci U S A. 2025;122:e2517715122.
    

    >> Share

    
    
37. BANDINI M, Ghone D, Evans EL 3rd, Suzuki A, et al
    HIV-1 Vif and Vpr cooperatively modulate the cell cycle to maximize per-cell virion production.
    Proc Natl Acad Sci U S A. 2025;122:e2511502122.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share